Pharma Focus Asia

Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto

Friday, September 16, 2022

Avicanna Inc., a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has expanded its research collaboration in field of Epilepsy with a new collaboration with the University of Toronto and Dr. Mac Burnham’s research team to explore the efficacy of Avicanna’s proprietary formulations in pre-clinical models for Epilepsy.

New research collaboration with University of Toronto

The research collaboration led by Dr. Mac Burnham’s team will explore the efficacy of Avicanna’s drug candidates including AVCN319302 in animal models for Epilepsy. In addition, the research collaboration will evaluate the anti-seizure properties of rare cannabinoids in isolation and in combination. Dr. Burnham is a professor emeritus of pharmacology and toxicology at the University of Toronto’s Temerty Faculty of Medicine, and is a co-director of EpLink, the Ontario Brain Institute’s Epilepsy Research Program. He has over 150 publications and has contributed greatly to the advancement of anti-seizure therapies.

According to Dr. Burnham, “The cannabinoids, alone and in combination, are some of the most promising antiseizure drugs that I have seen in many years of research.”

Ongoing research collaboration with University Health Network

The research by Dr. Burnham’s team will expand on an existing collaboration with the University Health Network and Dr. Peter Carlen, a professor of medicine and physiology at Temerty Faculty of Medicine, and senior scientist at the Toronto Western Research Institute.

The previously reported, electrophysiological studies on seizure induced wildtype cortical slices determined that Avicanna’s proprietary drug candidate, AVCN319302, had significant anti-convulsant effects and demonstrated strong potential to treat patients diagnosed with intractable forms of Epilepsies and those at risk of seizure-induced Sudden Unexpected Death.

“We are excited to continue expanding our research on cannabinoids and their anti-seizure properties in the field of Epilepsy and to be doing so with leading Canadian institutions and key opinion leaders. In parallel, we are also excited by the rate of early acceptance of our medical cannabis formulation (RHO Phyto Micro Drop 50 CBD) by epilepsy patients, where such early acceptance also provides real world data and evidence. The combination of real-world evidence and ongoing research collaborations enable us to further develop our pharmaceutical pipeline and further progress our drug candidate in the field of epilepsy,” noted Dr. Karolina Urban, Vice President Scientific and Medical Affairs.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024